Mobia Medical (NASDAQ:MOBI) Announces Quarterly Earnings Results

Mobia Medical (NASDAQ:MOBI) posted its quarterly earnings results on Tuesday. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27), FiscalAI reports. The business had revenue of $13.51 million during the quarter. Mobia Medical’s revenue for the quarter was up 102.4% compared to the same quarter last year.

Here are the key takeaways from Mobia Medical’s conference call:

• Q2 revenue doubled year over year to $13.5 million, supported by broader Vivistim adoption, while gross margin increased to 83.2%. Management initiated 2026 revenue guidance of $54 million to $56 million, implying 69% to 75% growth.
• Commercial expansion continued, with average active territories rising 92% year over year to 35.5 and approximately 367 Vivistim units sold in the quarter. Management expects to add roughly four to five active territories in the second half while maintaining a measured expansion strategy.
• The May IPO generated approximately $134 million in net proceeds, leaving $177.1 million in cash and equivalents at quarter-end. The company plans to invest primarily in sales hiring, geographic expansion, patient awareness, and clinical evidence.
• CMS assigned Vivistim’s Category 1 CPT code to New Technology APC 1580 for 2026, representing Medicare reimbursement of approximately $45,000; however, the proposed 2027 payment classification is not final until November. Commercial payer coverage remains a multiyear development effort, though some insurers are already paying claims.
• Operating expenses grew faster than revenue, with SG&A up 85% to $26.9 million and R&D up 61% to $2.3 million. Net loss increased to $21.0 million, including a one-time, non-cash $4 million charge related to the conversion of convertible notes.

Mobia Medical Stock Performance

Shares of Mobia Medical stock opened at $12.58 on Wednesday. The firm has a fifty day moving average of $12.54. The firm has a market cap of $418.27 million and a PE ratio of -0.65. Mobia Medical has a 12-month low of $10.19 and a 12-month high of $15.29.

Wall Street Analyst Weigh In

MOBI has been the subject of a number of recent research reports. JPMorgan Chase & Co. started coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They issued an “overweight” rating and a $15.00 price target for the company. BTIG Research reissued a “buy” rating and issued a $19.00 price objective on shares of Mobia Medical in a research report on Wednesday. Bank of America started coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They issued a “buy” rating and a $16.00 price objective on the stock. Wall Street Zen raised shares of Mobia Medical from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th. Finally, Wolfe Research began coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They set an “outperform” rating for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Mobia Medical currently has a consensus rating of “Moderate Buy” and an average target price of $20.25.

Insider Buying and Selling

In related news, CFO Nelson Bunker Curnes purchased 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 9th. The shares were purchased at an average cost of $12.79 per share, for a total transaction of $63,950.00. Following the purchase, the chief financial officer directly owned 366,997 shares of the company’s stock, valued at $4,693,891.63. The trade was a 1.38% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Key Mobia Medical News

Here are the key news stories impacting Mobia Medical this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set a $19.00 price target, implying substantial upside from the recent trading level. The endorsement reflects confidence in Mobia Medical’s growth prospects. Benzinga analyst rating report
• Positive Sentiment: Second-quarter revenue rose 102.4% year over year to $13.51 million, while gross margin reached 83.2%. Management also forecast 2026 revenue of $54 million to $56 million, above the approximately $53.5 million analyst consensus, representing expected growth of roughly 69% to 75%. Mobia Medical second-quarter 2026 financial results
• Positive Sentiment: Mobia Medical highlighted two-year VNS-REHAB follow-up data showing durable improvements in upper-limb motor function, daily living activities and quality of life. The company also completed its IPO, raising approximately $134 million in net proceeds, strengthening its funding position. Clinical data and IPO highlights
• Neutral Sentiment: The IPO proceeds and continued commercialization could support expansion, but investors will likely focus on how quickly the company converts revenue growth into profitability.
• Negative Sentiment: Mobia Medical reported a second-quarter loss of $1.10 per share, wider than the analyst consensus loss of $0.83 per share. The company remains unprofitable, with analysts expecting a full-year loss of approximately $2.50 per share, creating pressure despite strong sales growth. Mobia Medical earnings report

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.